Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Turkish Translation
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kasner, S. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kasner, S. E.
Related Collections
Right arrow Stroke prevention
Right arrow All Clinical trials
Right arrow All Cerebrovascular disease/Stroke
Right arrow Clinical trials Randomized controlled (CONSORT agreement)
Right arrow Infarction
NEUROLOGY 2006;67:1275-1278
© 2006 American Academy of Neurology
Brief Communications

Warfarin vs aspirin for symptomatic intracranial stenosis: Subgroup analyses from WASID

S. E. Kasner, MD, M. J. Lynn, MS, M. I. Chimowitz, MB, ChB, M. R. Frankel, MD, H. Howlett-Smith, RN, V. S. Hertzberg, PhD, S. Chaturvedi, MD, S. R. Levine, MD, B. J. Stern, MD, C. G. Benesch, MD, T. G. Jovin, MD, C. A. Sila, MD, J. G. Romano, MD for the Warfarin Aspirin Symptomatic Intracranial Disease (WASID) Trial Investigators*

From the Department of Neurology (S.E.K.), University of Pennsylvania Medical Center, Philadelphia, PA; Department of Biostatistics (M.J.L., V.S.H.), Rollins School of Public Health, Emory University, Atlanta, GA; Department of Neurology (M.I.C., M.R.F., H.-H.S., B.J.S.), Emory University School of Medicine, Atlanta, GA; Department of Neurology (S.C.), Wayne State University, Detroit, MI; Department of Neurology (S.R.L.), Mt. Sinai School of Medicine, New York, NY; Department of Neurology (B.J.S.), University of Maryland, Baltimore, MD; Department of Neurology (C.G.B.), University of Rochester School of Medicine, Rochester, NY; Department of Neurology (T.G.J.), University of Pittsburgh School of Medicine, Pittsburgh, PA; Department of Neurology (C.A.S.), Cleveland Clinic Foundation, Cleveland, OH; Department of Neurology (J.G.R.), University of Miami Medical School, Miami, FL.

Address correspondence and reprint requests to Dr. Scott E. Kasner, Department of Neurology, University of Pennsylvania, 3 W Gates Building, 3400 Spruce Street, Philadelphia, PA 19104; e-mail: kasner{at}mail.med.upenn.edu

The WASID trial showed no advantage of warfarin over aspirin for preventing the primary endpoint of ischemic stroke, brain hemorrhage, or vascular death. In analyses of selected subgroups, there was no definite benefit from warfarin. Warfarin reduced the risk of the primary endpoint among patients with basilar artery stenosis, but there was no reduction in stroke in the basilar artery territory or benefit for vertebral artery stenosis or posterior circulation disease in general.

*See the appendix in reference 1 for a list of WASID Investigators.

Funded by a research grant (1R01 NS36643, Principal Investigator: M.I. Chimowitz) from the U.S. Public Health Service, National Institute of Neurological Disorders and Stroke. In addition, the following general clinical research centers, funded by the NIH, provided local support for the evaluation of patients in the trial: Emory University (M01 RR00039), Case Western University, MetroHealth Medical Center (5M01 RR00080), San Francisco General Hospital (M01 RR00083-42), Johns Hopkins University School of Medicine (M01 RR000052), Indiana University School of Medicine (5M01 RR000750-32), Cedars-Sinai Hospital (M01 RR00425), and the University of Maryland (M01 RR165001).

The U.S. Food and Drug Administration assigned an IND number of 57,138 for Coumadin (warfarin sodium) for this trial.

Disclosure: See the appendix at the end of this article for disclosures.

Received April 4, 2006. Accepted in final form June 6, 2006.




This article has been cited by other articles:


Home page
 NeurologyHome page
O. O. Zaidat, R. Klucznik, M. J. Alexander, J. Chaloupka, H. Lutsep, S. Barnwell, M. Mawad, B. Lane, M. J. Lynn, M. Chimowitz, et al.
The NIH registry on use of the Wingspan stent for symptomatic70-99% intracranial arterial stenosis
Neurology, April 22, 2008; 70(17): 1518 - 1524.
[Abstract] [Full Text] [PDF]

Home page
 StrokeHome page
D. Fiorella, E. I. Levy, A. Turk, H. H. Woo, F. C. Albuquerque, and C. G. McDougall
Response to Letter by Gupta et al
Stroke, September 1, 2007; 38(9): e81 - e82.
[Full Text] [PDF]

Home page
 StrokeHome page
S. E. Kasner
Middle Cerebral Artery Stenosis: Stenting Is One of the Options: No
Stroke, April 1, 2007; 38(4): 1420 - 1421.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2006 by AAN Enterprises, Inc.